The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | Phase Ib/IIa trial of fostrox and lenvatinib in advanced HCC
Hong Jae Chon, MD, PhD, CHA University, Seongnam, South Korea, discusses findings from a Phase Ib/IIa trial (NCT03781934) of fostroxacitabine bralpamide (fostrox) and lenvatinib in second-line advanced hepatocellular carcinoma (HCC), highlighting the combination therapy’s encouraging anti-tumor activity with an objective response rate of 24% and median progression-free survival of 6.7 months. Dr Chon notes that the addition of fostrox to lenvatinib may provide additional clinical benefit compared to lenvatinib alone, with a manageable safety profile and no evidence of treatment-related deterioration in liver function. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
